Trial Profile
Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease; Asperger syndrome; Autistic disorder; Cognition disorders; Dementia
- Focus Pharmacodynamics
- 20 Jul 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 07 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2010 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.